Nootropics and Supplements
Linas JuozenasShare
What a compound changes—and what it cannot replace
A substance may correct a deficiency, treat a diagnosed disorder, delay sleepiness or alter performance on one laboratory task. Those are different achievements. None automatically means that an already healthy person has become more intelligent, wiser, safer or better able to learn.
“Nootropic” is a promise, not an evidence grade
Corneliu Giurgea introduced the nootropic idea in the early 1970s with a demanding ideal: a compound should support learning or memory while protecting the brain and avoiding the usual liabilities of psychotropic drugs. Modern marketing uses the word much more loosely—for caffeine, vitamins, mushrooms, prescription medicines and unapproved research chemicals alike.1
The label therefore tells us almost nothing. A serious evaluation begins with the exact product, person, purpose, outcome, duration, comparison and risk—not whether the package says “natural,” “smart,” “adaptogenic” or “clinically studied.” A systematic review of ingredients marketed to healthy adults found a low-certainty and incomplete evidence base, compounded by uncertainty about what products actually contain.2
Intelligence is not one chemical level
General intelligence reflects broad capacities for learning, reasoning, abstraction and solving unfamiliar problems. Expertise adds organized knowledge, trained perception and judgement. Wisdom also requires values, experience, self-correction and the ability to foresee human consequences. No single transmitter, supplement or wakefulness score captures this architecture.
Exceptional minds deserve protection: adequate sleep, health care, education, autonomy, uninterrupted thinking time, fair credit and trustworthy collaborators. A stimulant may extend a working session, but it cannot manufacture years of understanding—or make the accumulated knowledge in a living brain disposable.
Four questions hidden inside one label
The same substance may look impressive in one context and irrelevant—or unsafe—in another. The first task is to identify the baseline problem being changed.
| Question | A suitable population | What success would mean | What it would not prove |
|---|---|---|---|
| Does it correct a deficiency? | People with a verified nutrient deficiency or impaired absorption. | Biochemical correction accompanied by relevant symptom or functional improvement. | That more of the nutrient improves cognition above sufficiency. |
| Does it treat a disorder? | People meeting defined diagnostic criteria. | Clinically meaningful benefit compared with placebo, usual care or another treatment. | That the medicine is appropriate for healthy people or improves general intelligence. |
| Does it counter an adverse state? | People who are sleep-deprived, fatigued or working at an unusual circadian time. | Temporary improvement in wakefulness or task performance under that condition. | That lost sleep has been repaid or memory consolidation restored. |
| Does it enhance healthy cognition? | Healthy, adequately rested people without the targeted deficiency. | Replicated improvement on meaningful outcomes, ideally retained and transferable. | Long-term benefit unless harms, tolerance and discontinuation are also studied. |
- MoleculeReaches a biological target
- BiomarkerChanges a measurable signal
- TaskAlters one test result
- LearningImproves later unaided retention
- LifeHelps meaningful functioning
- Net benefitStill helps after trade-offs
A chain of plausibility is not a chain of proof
Receptor binding, antioxidant activity, increased cerebral blood flow or a change in a growth-factor measurement can explain how an effect might occur. They do not demonstrate that a person remembers more, reasons better or functions more safely. Each step in the chain needs evidence, and effects may disappear—or reverse—when the dose, population, formulation or timescale changes.
How to judge cognitive evidence
A letter grade hides the details that decide whether a result applies. Use six coordinates instead.
Size matters
A statistically detectable average may still be too small to matter. Ask whether outcomes were prespecified, confidence intervals include trivial effects and improvement reached everyday function.
Controls matter
Practice, expectation and selective dropout can imitate benefit. Strong trials use credible comparisons, report attrition and distinguish a brief state change from retained learning.
Transfer matters
One faster computerized response is not automatically better judgement, study or expertise. Broad claims require durable improvement across unfamiliar and meaningful tasks.
Find the bottleneck before the bottle
Many cognitive complaints arise from sleep, illness, medication, stress, pain, sensory access or work design—not a missing nootropic.
Sleep
Stimulation may hide sleepiness without repairing circadian disruption, apnea or lost memory consolidation.
Health
Anemia, B12 deficiency, thyroid disease, infection and metabolic illness require assessment of the cause.
Substances
Medicines, alcohol, nicotine withdrawal and combinations can alter attention, sleep and thinking.
Environment
Interruption, anxiety, poor teaching or excessive workload can resemble a biological attention problem.
- Describe the problem observably: sleepiness, forgetting, distraction, slow reading or poor understanding?
- Record timing and links with sleep, food, pain, mood, medication and environment.
- Decide whether the target is performance now, learning next week or health years later.
- Review all medicines, supplements, drinks and recreational substances together.
- Use hearing, vision and accessibility support when access—not intelligence—is the obstacle.
- New confusion, weakness, speech change, severe headache or rapid decline requires medical assessment.
Restoration can look like enhancement
Correcting a deficiency, sleep disorder or illness may produce a large improvement. That deserves celebration, but it does not prove that the same intervention pushes an adequately nourished, healthy person above baseline.
A practical evidence map
This is not a shopping list. It marks the boundary around each category's most defensible claim.
| Category | Where evidence is relevant | What can responsibly be concluded |
|---|---|---|
| Caffeine ± L-theanine | Acute alertness and selected attention outcomes. | Real short-term effects; not durable learning, universal “calm focus” or replacement for sleep. |
| B12 or iron | Verified deficiency, malabsorption or relevant anemia. | Correction may restore affected function; surplus is not superior and iron excess can harm. |
| Omega-3 | Nutrition and particular medical contexts. | Biologically important, but supplements have not proved universal prevention of cognitive decline. |
| Creatine | Energy metabolism and selected cognitive domains. | Promising in some contexts, not established as a general cognitive enhancer. |
| Bacopa | Repeated use of particular standardized extracts. | Small memory or attention signals; products, methods and tolerability vary. |
| Ginkgo | Mainly cognitive impairment or dementia. | Possible symptomatic benefit in some dementia studies; little or no MCI benefit in the latest Cochrane review. |
| Lion’s mane / rhodiola | Small preliminary trials or fatigue and stress claims. | Research interest remains; evidence is insufficient for broad cognitive promises. |
| Prescription medicines | Defined diagnoses and selected patients. | Can be important treatment; healthy-person effects are narrower and risks remain. |
| Internet research products | Sometimes limited or country-specific medical histories. | Availability does not establish approval, legality, identity, safety or useful cognition. |
Caffeine: alertness with a clock attached
Caffeine is the clearest example of a substance that genuinely changes cognition while also illustrating why timing, tolerance and sleep belong inside the result.
What it can do
By blocking adenosine receptors, caffeine reduces the felt pressure to sleep and can improve vigilance, reaction time and attention. Benefits are often more visible when a person is tired or performing monotonous work; effects on complex judgement, learning and creativity are less uniform.3
A review of eleven randomized placebo-controlled studies found that caffeine combined with L-theanine produced moderate acute effects on alertness and some attention measures during the first two hours. The pattern was outcome-specific, and the analysis suggested caffeine dose contributed strongly to the effect.3
What the immediate score hides
Repeated use can produce tolerance and physical dependence. Withdrawal may cause headache, fatigue and poorer concentration, so part of a habitual user’s apparent “boost” may be reversal of withdrawal. Individual response varies with genetics, medication, pregnancy, anxiety, cardiovascular status and habitual exposure.
Caffeine also delays sleep and can reduce sleep duration or quality. A 2023 systematic review and meta-analysis found measurable effects on subsequent sleep, which means an afternoon performance gain can borrow from the learning, mood and attention available the next day.4
Safety benchmarks are boundaries, not performance targets
EFSA concluded that, for healthy non-pregnant adults, single intakes up to 200 mg and habitual intake up to 400 mg per day generally did not raise safety concerns; it used a lower 200 mg daily benchmark during pregnancy and noted insufficient information to derive the same adult benchmark for children and adolescents.5 These values do not guarantee comfort or benefit for every person, and they do not recommend consuming the maximum. Product caffeine content can vary widely, and concentrated powders make measurement errors especially dangerous.
Use the whole day as the unit of analysis
A responsible caffeine decision asks whether it improved the work that mattered, whether it shifted bedtime, whether sleep quality changed, whether anxiety or heart symptoms appeared, and whether the same task could have been improved by sleep, light, movement, food or a better schedule. No energy drink neutralizes alcohol impairment, and subjective wakefulness should never be mistaken for safe driving or sound judgement.
Nutrients and creatine: correction is not unlimited enhancement
The brain needs nutrients. That does not mean every extra capsule improves cognition once requirements are met.
Vitamin B12
Deficiency can cause serious neurological symptoms and should be corrected. Broad trials in older adults, however, generally have not shown cognitive improvement from B12 or combined B vitamins despite lower homocysteine.6 Malabsorption and some medicines justify assessment, not automatic high dosing.
Iron
Iron-deficiency anemia can impair energy, concentration and work performance.7 Treatment should address both deficiency and its cause. Excess iron can injure the gastrointestinal tract, interact with medicines and become dangerous in overdose or iron-overload disorders.
Broad vitamin use
A Cochrane review found little evidence that broad vitamin or mineral supplementation maintains cognition in cognitively healthy middle-aged and older adults.8 Good nutrition and deficiency treatment are different claims from a universal anti-decline pill.
Omega-3: important biology, narrower supplement claims
DHA and EPA matter biologically, and nutrient-rich foods can support health. Yet a Cochrane review did not find evidence that omega-3 supplements prevented cognitive decline or dementia in cognitively healthy older adults during the studied periods.9 A food pattern, a diagnosed condition and a concentrated capsule are not interchangeable exposures.
Creatine: a lesson in scientific disagreement
A 2024 meta-analysis of sixteen randomized trials reported small average benefits for memory and selected timed outcomes, but not overall cognition or executive function; certainty differed by domain.10 EFSA, evaluating a public health claim for healthy adults, concluded that cause and effect had not been established across cognitive domains.11
Those assessments ask different questions, but together support a restrained conclusion: creatine is promising in some contexts, not established as a general intelligence enhancer.
Botanicals and fungi: exact extracts, modest signals and large uncertainty
Species, plant part, extraction, storage, contaminants and active-constituent profile can change the intervention. Evidence belongs to the tested preparation—not to “natural” as a category.
Bacopa monnieri
Reviews of small randomized trials suggest that repeated use of certain extracts may affect memory recall or speed of attention after weeks of use.1213 Product heterogeneity and gastrointestinal effects prevent a result for one extract from validating every powder, tea or blend.
Ginkgo biloba
A 2026 Cochrane review of 82 studies found probably little or no benefit for mild cognitive impairment at six months. Some dementia studies suggested symptomatic benefit, but estimates varied and confidence was limited.14 That does not establish healthy-person enhancement or prevention.
Lion’s mane
One trial of thirty adults with mild cognitive impairment reported better scores during sixteen weeks of Hericium erinaceus, followed by decline after stopping.15 It is a reason for replication, not proof that any mushroom product grows a more intelligent brain.
Rhodiola rosea
Rhodiola is promoted for fatigue, stress and cognition, but NCCIH finds insufficient reliable evidence for any health-related purpose. Insomnia, dizziness, headache and reported drug interactions also matter.16
“Adaptogen” is not a clinical endpoint
A marketing category cannot prove that a product normalizes stress. Meaningful claims still require a defined population, verified preparation, credible comparator, validated outcome and adequate safety data.
Prescription medicines and unapproved compounds
A medicine can transform life for the condition it treats while remaining inappropriate for unsupervised use by someone without that condition.
Modafinil
Modafinil is indicated for excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift-work disorder; in apnea it treats sleepiness, not airway obstruction.17 A review in healthy, rested adults found improvements on some tasks, not a uniform rise in intelligence.18
Prescribing information warns about serious rash, psychiatric symptoms and relevant cardiovascular concerns. It may reduce steroidal-contraceptive effectiveness during use and for one month after stopping.17
Prescription stimulants
Methylphenidate and amphetamine medicines are valuable treatments for appropriately diagnosed conditions. In healthy adults, meta-analysis found small effects in selected control, working-memory and episodic-memory outcomes—not a wholesale transformation of achievement.19 FDA warnings emphasize misuse, addiction, overdose and death risks.20
Nicotine
Nicotine can transiently alter attention, but it is addictive; withdrawal itself impairs concentration and memory.21 Nicotine replacement can help treat tobacco dependence. That legitimate use does not make nicotine a sensible general cognitive supplement.
Racetams, noopept, phenibut and related products
Online availability does not prove approval, lawful marketing, pharmaceutical quality or safe self-use. FDA has cited unlawful drug claims for several such products and stated that the named products were not generally recognized as safe and effective for those uses.22 Classification and import rules differ across jurisdictions.
Do not borrow another person’s diagnosis—or prescription
Sharing medicine removes the assessment, interaction review and follow-up that determine whether expected benefit outweighs risk. People who need treatment deserve reliable care without stigma; people considering nonmedical use deserve an equally honest account of limits.
Safety, interactions and why “stacks” multiply uncertainty
Safety includes identity, dose accuracy, interactions, delayed effects, sleep, dependence, pregnancy, organ function and the ability to stop—not merely feeling fine today.
- Identity: Does the actual batch contain the stated ingredient and amount?
- Interaction: Could it affect medicines, blood pressure, bleeding, sedation, stimulation or contraception?
- Duplication: Is one stimulant, vitamin or botanical repeated across products?
- Timing: Does today's benefit disturb sleep, appetite or tomorrow's learning?
- Population: Were age, pregnancy, organ disease and psychiatric vulnerability studied?
- Exit: Are tolerance, withdrawal, rebound and loss of effect understood?
The combinatorial problem
Each added ingredient creates new metabolic, physiological and attribution questions. Compounds can amplify the same variable, conceal one another's effects or make it impossible to identify what helped or harmed. Proprietary blends may hide the individual amounts. “No interaction data” usually means unknown—not compatible.
Third-party testing answers only part of the question
Certification may support identity and screening for selected contaminants or prohibited substances. It does not prove cognitive benefit, personal suitability, freedom from interaction or long-term safety.23
Stop rules protect intelligence
For any medically appropriate trial, define meaningful benefit, relevant adverse changes and a review point. Continuing because money was spent, because stopping feels like failure or because withdrawal temporarily worsens baseline is not evidence of net benefit.
Product quality and regulation
“Sold legally,” “FDA registered,” “made in a certified facility” and “clinically tested” are not synonyms for approved, effective or appropriate.
United States
FDA does not approve dietary supplements before sale. Manufacturers initially carry responsibility for safety, labeling and compliance, while much oversight is post-market; FDA also does not routinely test every product before sale. A supplement represented as treating, preventing or curing disease is regulated as a drug.24 Label serving size and facility registration do not establish an approved cognitive dose or efficacy.
European Union
EU law provides a food-supplement framework while member states retain important responsibilities.25 Nutrition and health claims may not be false, ambiguous or misleading.26 Some ingredients may require novel-food authorization; the Commission catalogue is guidance, not the final legal decision in every case.27
| Phrase | May indicate | Does not establish |
|---|---|---|
| Natural | A biological or mineral source. | Purity, safety, gentle effects or no interactions. |
| Standardized | A marker controlled within a range. | That the marker causes benefit or matches successful trials. |
| Clinically tested | Some product or ingredient entered a study. | A successful trial of this exact product and claim. |
| Third-party certified | Selected identity or contaminant standards were checked. | Effectiveness, complete purity or zero athlete risk. |
Sport and professional rules
WADA updates its Prohibited List annually. Athletes need the current list, exact substance, therapeutic-use requirements and sport guidance—not an old article or “athlete safe” advertisement.28
Ethics, performance pressure and brain protection
The question is not only whether a compound changes performance. It is whether people remain free, informed, healthy and fairly recognized.
Consent without coercion
No student, employee, soldier, athlete or creator should be pressured to use a psychoactive substance to meet an unhealthy workload or prove commitment. “Voluntary” use is not fully voluntary when refusal threatens belonging, employment, grades or safety.
Support before extraction
Organizations should correct sleep-destroying schedules, harassment, inaccessible environments and impossible workloads before asking individuals to chemically adapt. A brilliant person is not a productivity reservoir to be mined until illness; protecting health preserves knowledge and future contribution.
Credit the person, not the product
A tool may alter state, but it does not write the argument, accumulate the expertise or assume ethical responsibility. People deserve fair credit for cultivated ability, including those whose intelligence is quiet, autistic, introverted or communicated unconventionally.
Alcohol is not exempt because it is familiar
Alcohol is ethanol: a psychoactive, intoxicating and dependence-producing drug. It disrupts communication in the brain and can impair judgement, memory and coordination.29 Caffeine may make an intoxicated person feel less sleepy without restoring sober decision-making. No “recovery stack” makes hazardous drinking cognitively safe, and belonging or celebration should never require intoxication.
Comparative risk should remain precise. Different substances have different hazards depending on dose, frequency, route, purity, age, health, interactions and context. Naming alcohol’s harms does not make another drug harmless; acknowledging a medicine’s risk does not erase its value for a diagnosed patient.
Freedom includes the right to remain chemically unmodified
People should be able to ask for rest, quiet, accommodations, treatment, better teaching or a different schedule without being told to ingest something. They should also be able to receive evidence-based medication for a genuine condition without stigma. Ethical support protects both choices.
The CLEAR evaluation protocol
Use this framework to expose uncertainty before enthusiasm becomes commitment.
C — Clarify
Replace “better focus” with a falsifiable target: staying awake during a necessary shift, reading for forty minutes, recalling material after a week or reducing diagnosed impairment.
L — Locate
Review sleep, meals, pain, mood, hearing, vision, medicines, alcohol, nicotine, anemia risk and work design. Persistent or worsening symptoms deserve assessment.
E — Evaluate
Find the strongest human evidence for the same population and preparation. Examine comparators, duration, outcomes and adverse events; rank systematic reviews and preregistered trials above mechanisms and testimonials.
A — Audit
Put every medicine, supplement, drink and recreational drug on one list. Check duplicate ingredients and interactions with a pharmacist or clinician, then verify batch quality and current legal or sport status.
R — Review
Reassess the original outcome and relevant harms at a predefined point. An absent, trivial, escalating or sleep-destroying benefit is not rescued by an attractive mechanism.
Test what remains without the aid
For learning, measure later unaided recall, explanation and application. For treatment, use outcomes agreed with the prescriber. Assisted performance and developed ability are both real, but they are not the same result.
What better research should solve
The field needs larger claims only after it earns clearer answers.
Verified products
Trials should chemically characterize the exact formulation and retain samples for independent analysis. Without product verification, even a good clinical design may not tell consumers whether a later commercial batch resembles the intervention.
Meaningful outcomes
Researchers should preregister a small number of outcomes, include delayed and unaided testing, report absolute effects and ask whether changes improve daily functioning—not merely whether one of many computerized measures reached significance.
Longer observation
Acute studies cannot reveal tolerance, dependence, sleep debt, withdrawal, cardiovascular consequences or whether a benefit persists. Trials need discontinuation periods and transparent reporting of all adverse events.
Real diversity
Effects may differ by diet, deficiency, age, sex, genetics, illness, sleep state and medication. Subgroup hypotheses should be prespecified and adequately powered rather than discovered after the fact.
Independent replication
Small industries can produce many studies without producing independent knowledge. Replication by teams without financial dependence on the product is particularly valuable when the intervention is easy to market before evidence matures.
Head-to-head value
A supplement should eventually be compared with the best realistic alternative: sleep treatment, structured breaks, exercise, food, psychotherapy, tutoring or established medication—not only an inert placebo.
Precision medicine may eventually identify people who respond unusually well or poorly, but consumer genetic panels cannot currently convert an uncertain general effect into a guaranteed personal prescription. Personalization is only as good as the underlying causal evidence, assay validity and clinical interpretation.
Myths worth retiring
These corrections preserve genuine possibilities while removing conclusions the evidence cannot carry.
Protect the mind before trying to push it
Nootropics are not one class with one answer. A nutrient can correct deficiency. A medicine can treat a disorder. Caffeine can improve alertness. A botanical can produce an early research signal. Each claim is meaningful only inside its population, formulation, outcome, timescale and risk.
The strongest strategy is not reflexive acceptance or dismissal. It is disciplined discrimination: diagnose the bottleneck, preserve sleep and health, value genuine treatment, demand exact evidence, reject coercion, verify products and measure net functioning. Intelligence deserves development and celebration—and because it is embodied in living brains, it also deserves protection from avoidable injury, dependence, exploitation and confident marketing that outruns knowledge.
Sources and further reading
Primary studies, systematic reviews and official regulatory or health resources supporting this guide.
- Giurgea. The “nootropic” approach to the pharmacology of the integrative activity of the brain (1973).
- Crawford, Boyd & Deuster. Dietary supplement ingredients for optimizing cognitive performance among healthy adults: a systematic review (2021).
- Camfield et al. Acute effects of tea constituents L-theanine, caffeine and epigallocatechin gallate on cognitive function and mood (2014).
- Gardiner et al. The effect of caffeine on subsequent sleep: a systematic review and meta-analysis (2023).
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the safety of caffeine (2015).
- NIH Office of Dietary Supplements. Vitamin B12: health professional fact sheet.
- NIH Office of Dietary Supplements. Iron: health professional fact sheet.
- Rutjes et al. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (2018).
- Sydenham, Dangour & Lim. Omega-3 fatty acid for the prevention of cognitive decline and dementia (2012).
- Xu et al. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis (2024; corrigendum 2025).
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. Creatine and improvement in cognitive function: evaluation of a health claim (2024).
- Kongkeaw et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract (2014).
- Pase et al. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials (2012).
- Wieland et al. Ginkgo biloba for cognitive impairment and dementia (Cochrane Review, 2026).
- Mori et al. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment (2009).
- National Center for Complementary and Integrative Health. Rhodiola: usefulness and safety.
- U.S. National Library of Medicine. Modafinil prescribing information (DailyMed).
- Battleday & Brem. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review (2015).
- Ilieva, Hook & Farah. Prescription stimulants’ effects on healthy inhibitory control, working memory and episodic memory: a meta-analysis (2015).
- U.S. Food and Drug Administration. Updated warnings for prescription stimulants (2023).
- National Institute on Drug Abuse. Is nicotine addictive?
- U.S. Food and Drug Administration. Warning letter to Peak Nootropics / Advanced Nootropics (2019).
- Operation Supplement Safety. Why is third-party certification important for dietary supplements?
- U.S. Food and Drug Administration. Questions and answers on dietary supplements.
- European Parliament and Council. Directive 2002/46/EC on food supplements.
- European Parliament and Council. Regulation (EC) No 1924/2006: nutrition and health claims made on foods.
- European Commission. Novel Food Catalogue.
- World Anti-Doping Agency. The Prohibited List.
- National Institute on Alcohol Abuse and Alcoholism. Alcohol and the brain: an overview.
Educational note: This article explains general evidence, safety and regulation. It does not diagnose a cognitive symptom, recommend a supplement dose, instruct readers to obtain prescription or unapproved drugs, or replace individualized advice from a qualified physician, pharmacist or registered dietitian. Products, labels, laws and sport rules change; verify the exact item and current jurisdiction.
Intelligence Unleashed series
- Cognitive Training and Mental Exercises
- Learning New Skills
- Mindfulness and Meditation
- Memory Improvement Techniques
- Critical Thinking and Problem-Solving
- Healthy Lifestyle Habits
- Social Engagement
- Technology and Tools
- Nootropics and Supplements